RT Journal Article
SR Electronic
T1 A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.12.21253373
DO 10.1101/2021.03.12.21253373
A1 O’Donnell, Max R.
A1 Grinsztejn, Beatriz
A1 Cummings, Matthew J.
A1 Justman, Jessica
A1 Lamb, Matthew R.
A1 Eckhardt, Christina M.
A1 Philip, Neena M.
A1 Cheung, Ying Kuen
A1 Gupta, Vinay
A1 João, Esau
A1 Pilotto, Jose Henrique
A1 Diniz, Maria Pia
A1 Cardoso, Sandra Wagner
A1 Abrams, Darryl
A1 Rajagopalan, Kartik
A1 Borden, Sarah
A1 Wolf, Allison
A1 Sidi, Leon Claude
A1 Vizzoni, Alexandre
A1 Veloso, Valdilea G.
A1 Bitan, Zachary C.
A1 Scotto, Dawn E.
A1 Meyer, Benjamin J.
A1 Jacobson, Samuel D.
A1 Kantor, Alex
A1 Mishra, Nischay
A1 Chauhan, Lokendra V.
A1 Stone, Elizabeth
A1 Dei Zotti, Flavia
A1 La Carpia, Francesca
A1 Hudson, Krystalyn E.
A1 Ferrera, Stephen A.
A1 Schwartz, Joseph
A1 Stotler, Brie
A1 Lin, Wen-Hsuan
A1 Wontakal, Sandeep
A1 Shaz, Beth
A1 Briese, Thomas
A1 Hod, Eldad A.
A1 Spitalnik, Steven L.
A1 Eisenberger, Andrew
A1 Lipkin, W. Ian
YR 2021
UL http://medrxiv.org/content/early/2021/03/13/2021.03.12.21253373.abstract
AB Background Although convalescent plasma has been widely used to treat severe coronavirus disease 2019 (COVID-19), data from randomized controlled trials that support its efficacy are limited.Objective To evaluate the clinical efficacy and safety of convalescent plasma among adults hospitalized with severe and critical COVID-19.Design Randomized, double-blind, controlled, multicenter, phase 2 trial conducted from April 21st to November 27th, 2020.Setting Five hospitals in New York City (NY, USA) and Rio de Janeiro (Brazil).Participants Hospitalized patients aged ≥18 years with laboratory-confirmed COVID-19, infiltrates on chest imaging and oxygen saturation ≤ 94% on room air or requirement for supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.Intervention Participants were randomized 2:1 to a single transfusion of either 1 unit of convalescent or normal control plasma.Measurements The primary outcome was clinical status at 28 days, measured using an ordinal scale and analyzed using a proportional odds model in the intention-to-treat population.Results Of 223 participants enrolled, 150 were randomized to receive convalescent plasma and 73 to normal control plasma. At 28 days, no significant improvement in clinical status was observed in participants randomized to convalescent plasma (with an odds ratio (OR) of a 1-point improvement in the scale: 1.50, 95% confidence interval (CI) 0.83-2.68, p=0.180).However, 28-day mortality was significantly lower in participants randomized to convalescent plasma versus control plasma (19/150 [12.6%] versus 18/73 [24.6%], OR 0.44, 95% CI 0.22-0.91, p=0.034). The median titer of anti-SARS-CoV-2 neutralizing antibody in infused convalescent plasma units was 1:160 (IQR 1:80-1:320). In a subset of nasopharyngeal swab samples (n=40) from Brazil that underwent genomic sequencing, no evidence of neutralization-escape mutants was detected. Serious adverse events occurred in 39/147 (27%) participants who received convalescent plasma and 26/72 (36%) participants who received control plasma.Limitations Some participants did not receive high-titer convalescent plasma.Conclusion In adults hospitalized with severe COVID-19, use of convalescent plasma was not associated with significant improvement in 28 days clinical status. The significant reduction in mortality associated with convalescent plasma, however, may warrant further evaluation.Registration ClinicalTrials.gov, NCT04359810Funding Amazon FoundationClinical Trial Registration ClinicalTrials.gov Identifier: NCT04359810Competing Interest StatementThe trial was funded by an unrestricted grant from the Amazon Foundation to Columbia University. The funder had no role in study design, data collection, data analysis or data interpretation. One co-author (VG) who contributed to writing of the manuscript is employed by Amazon Care.Clinical TrialClinicalTrials.gov Identifier: NCT04359810Clinical Protocols https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04504-x Funding StatementThe trial was funded by an unrestricted grant from the Amazon Foundation to Columbia University. The funder had no role in study design, data collection, data analysis or data interpretation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was conducted in accordance with Good Clinical Practice guidelines, the Declaration of Helsinki, and the Brazilian National Ethics Committee Resolution 466/12. Written informed consent was obtained from all participants or from their legally authorized representative. The trial protocol was approved by institutional review boards at CUIMC and at each site in Rio de Janeiro (14) and is registered at ClinicalTrials.gov (Identifier: NCT04359810). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will only be available as per the terms of the informed consent and institutional policies around data transfer.